Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed at Sun Yat-sen University Cancer Center in the phase I clinical study (Study ID: JSKN022-101) of ...

No needles needed. Dermatologists and editors agree—these peptide serums help plump, smooth, and firm skin for a youthful ...

Q2 2026 Earnings Call October 23, 2025 5:00 PM EDTCompany ParticipantsSarah LeeDaniel Shugar - Co-Founder, CEO ...

Vertex Pharmaceuticals Incorporated today announced the presentation of multiple abstracts demonstrating the clinical benefits of treatment with CFTR modulators, including the Company's most recently ...

There isn’t much difference between cult leaders like Rampal, or other leaders who weaponize faith for control, or patriarchs ...

Study Design The Phase 1/2 study ( NCT05732831) is a multicenter, open-label, first in human study in solid tumor patients whose tumor has a confirmed homozygous MTAP deletion. The first part of the ...

Levofloxacin-induced myopathy is a relatively under-recognized adverse effect. Here, we present a case of myopathy affecting the iliac and gluteal muscles caused by the administration of levofloxacin.

Prestigious peer-review validates HCB101's differentiated mechanism and translational strength. Clinical data show a nearly ...

Q3 2025 Earnings Call October 23, 2025 5:00 PM EDTCompany ParticipantsLynn Tyson - Executive Director of Investor ...

In a landmark collaboration between the Government of Jordan and Replit, a global leader in agentic software creation, the Ministry of Education has launched the pilot phase of "Siraj", an AI-powered ...

Data presented on outcomes following treatment with CFTR modulators add to growing body of evidence that reduced level of sweat chloride is associated with improved clinical outcomes, particularly ...